NCT02547025

Personalized Treatment for Refractory H Pylori Infection

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 126 (actual)
• Sponsor: Kaohsiung Veterans General Hospital. · Academic / Other
• Sex: All
• Age: 20 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

In this study, the investigators develop a personalized treatment according to culture-guided antibiotics plus high-dose proton-pump inhibitor and bismuth to treat refractory H pylori infection.

Detailed description

They are categorized into three groups: (1) patients who have positive result of culture with equal to or more than three susceptible antibiotics are treated by non-bismuth quadruple therapy (rabeprazole 20 mg q.d.s. and three effective antibiotics), (2) patients who have positive result of culture with one or two susceptible antibiotics are treated by bismuth-containing therapy (rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics), and (3) patients who have negative result of culture or whose culture data are unavailable will be treated by (rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.

Conditions

• Helicobacter Pylori Infection

Interventions

Type	Name	Description
DRUG	rabeprazole+3 antibiotics	(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
DRUG	rabeprazole+bismuth+2 antibiotics	(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
DRUG	rabeprazole+amox+tetr+levo	(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.

Timeline

• Start date: 2012-08-01
• Primary completion: 2021-10-31
• Completion: 2021-10-31
• First posted: 2015-09-11
• Last updated: 2023-10-26

Locations

1 site across 1 country: Taiwan